67 related articles for article (PubMed ID: 9191325)
1. Immunogenic properties of human papilloma virus type 16 (HPV-16) E5 polypeptide.
Gill D; Cason J; Punchard N
Biochem Soc Trans; 1997 May; 25(2):281S. PubMed ID: 9191325
[No Abstract] [Full Text] [Related]
2. Genital infection with human papillomavirus (HPV).
Tendler A; Ho GY; Kadish AS
Gynecol Oncol; 1999 Dec; 75(3):521-2. PubMed ID: 10627183
[No Abstract] [Full Text] [Related]
3. Generation and characterization of monoclonal antibodies against the E6 and E7 oncoproteins of HPV.
Wlazlo AP; Giles-Davis W; Clements A; Struble G; Marmorstein R; Ertl HC
Hybridoma; 2001 Aug; 20(4):257-63. PubMed ID: 11604112
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.
Reddy KJ; Banapour B; Anderson DE; Lee SH; Marquez JP; Carlos MP; Torres JV
Immunology; 2004 Jun; 112(2):321-7. PubMed ID: 15147575
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies of human papilloma vaccines in cervical cancer.
Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
[No Abstract] [Full Text] [Related]
6. [The role of human papillomavirus in carcinogenesis of cervical cancer and vaccination for HPV].
Kariya M; Fujii S
Uirusu; 2002 Dec; 52(2):287-93. PubMed ID: 12685321
[No Abstract] [Full Text] [Related]
7. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
8. Vaccination against human papillomaviruses shows great promise.
Lehtinen M; Paavonen J
Lancet; 2004 Nov 13-19; 364(9447):1731-2. PubMed ID: 15541429
[No Abstract] [Full Text] [Related]
9. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
10. Development of Novel Single-Chain Antibodies against the Hydrophobic HPV-16 E5 Protein.
Monjarás-Ávila C; Bernal-Silva S; Bach H
Biomed Res Int; 2018; 2018():5809028. PubMed ID: 30027096
[TBL] [Abstract][Full Text] [Related]
11. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.
Höhn H; Pilch H; Günzel S; Neukirch C; Freitag K; Necker A; Maeurer MJ
J Virol; 2000 Jul; 74(14):6632-6. PubMed ID: 10864677
[TBL] [Abstract][Full Text] [Related]
13. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
[TBL] [Abstract][Full Text] [Related]
14. Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients.
Fujii T; Matsushima Y; Yajima M; Sugimura T; Terada M
Jpn J Cancer Res; 1995 Jan; 86(1):28-34. PubMed ID: 7737906
[TBL] [Abstract][Full Text] [Related]
15. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes.
Tindle RW; Fernando GJ; Sterling JC; Frazer IH
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5887-91. PubMed ID: 1712110
[TBL] [Abstract][Full Text] [Related]
16. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
17. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations.
Nindl I; Zumbach K; Pawlita M; Teller K; Schneider A; Dürst M
J Infect Dis; 2000 May; 181(5):1764-7. PubMed ID: 10783118
[TBL] [Abstract][Full Text] [Related]
18. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
19. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
20. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
